Braxia Scientific Announces Participation at Canaccord Genuity 2021 Annual Growth Conference August 10-12
Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) announced its participation in the virtual Canaccord Genuity Annual Growth Conference, scheduled for August 10-12, 2021. CEO Dr. Roger McIntyre will present the company's initiatives focusing on novel therapeutics for depression and brain-based disorders. The presentation is set for August 10 at 11:30 a.m. ET. Braxia operates clinics providing ketamine treatments for mental health issues and is engaged in developing new drugs and delivery systems while striving to alleviate the burden of mental disorders.
- Participation in Canaccord Genuity Annual Growth Conference may enhance visibility and investor interest.
- CEO presentation on innovative treatments could attract potential partnerships or funding.
- Focus on developing novel therapeutics aligns with growing interest in mental health solutions.
- Reliance on regulatory approvals poses risks, as ketamine is a controlled substance.
- There are uncertainties regarding the efficacy and safety of ketamine and related therapies.
TORONTO, Aug. 6, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference. The conference will be held virtually on August 10-12, 2021.
Braxia Scientific CEO Dr. Roger McIntyre will deliver a presentation on the company's initiatives related to developing novel therapeutics and delivery systems for treating depression and other brain-based disorders, as well as its administration of patient care in its network of clinics.
Presentation details:
Date: Tuesday, August 10, 2021
Time: 11:30 a.m. ET
Event registration: https://bit.ly/3josIt3
For additional information on the conference, please CLICK HERE.
About Braxia Scientific Corp.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.
ON BEHALF OF THE BOARD
"Dr. Roger S. McIntyre"
Dr. Roger S. McIntyre
Chairman & CEO
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
Forward-looking Information Cautionary Statement
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements."
Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression and the potential for ketamine to treat other emerging psychiatric disorders, such as Bipolar Depression. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.
These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.
Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/braxia-scientific-announces-participation-at-canaccord-genuity-2021-annual-growth-conference-august-10-12-301350203.html
SOURCE Braxia Scientific Corp.
FAQ
What is Braxia Scientific's participation in the Canaccord Genuity 2021 Annual Growth Conference?
When will Braxia Scientific present at the Canaccord Genuity conference?
What does Braxia Scientific focus on in its research and treatments?
What are the risks associated with Braxia Scientific's therapies?
